Toronto Western Hospital
Toronto, Ontario, M3A2L8, Canada
Location status: Recruiting
NCT Number: NCT06374524
Spontaneous Intracranial Hypotension (SIH) is a debilitating neurological disorder caused by a cerebrospinal fluid leak (CSF), with an estimated incidence of 5 per 100,000 persons per year, of which mostly women between the ages of 35 years and 55 years. The typical presentation is moderate-to-severe orthostatic headache and several other possible neurological symptoms, that significantly impact patients' quality of life.
Treatment of SIH usually starts with conservative measures, consisting of strict supine bed rest, hydration, caffeine, and simple analgesics. The vast majority of patients will require invasive treatments for their CSF leak, such as epidural blood patches, fibrin glue patches, endovascular coiling, and/or surgical repair. These specialized treatments are only offered in tertiary care centers and require specialized personnel and resources, which implicates a certain waiting time for the patients before permanent treatment is offered. In the meantime, due to the lack of an effective and accessible alternative, patients continue to suffer.
The greater occipital nerve block (GONB) has been reported as a simple, safe, and effective treatment to provide short-to-intermediate term relief of migraine, cervicogenic headache, cluster headache, occipital neuralgia, and more recently, post-dural puncture headaches (PDPH). As the pathophysiology of intracranial hypotension caused by SIH or PDPH is very similar, it is stipulated that the effect of GONB will be similar for SIH patients. However, to date, no studies exploring the efficacy of GONB for SIH have been performed.
The investigators propose to do a prospective observational study to explore the outcome of GONB for SIH. GONB can serve as a bridge therapy to control the debilitating headache of SIH while patients are awaiting permanent SIH treatment. Moreover, GONB can be performed by physicians of different specialties including neurology, which makes it an accessible treatment for all patients. Lastly, by offering better symptom control, this intervention could potentially restore patients' ability to work and reduce healthcare costs.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Toronto, Ontario, M3A2L8, Canada
Location status: Recruiting
This a prospective observational study on 34 patients with SIH, recruited from the Toronto Western Hospital Intracranial Hypotension Clinic. Patients will receive an ultrasound-guided bilateral GONB of 5 mls of injectate of mix of local anesthetic with steroid. There is no comparator. Primary outcome is the change in intensity of headache at 30 minutes post-intervention. Secondary outcomes are change in intensity up to day 14 post-intervention, onset of headache, sitting endurance, change in SIH-associated central nervous system (CNS) symptoms, emotional functioning, patient satisfaction, analgesic consumption and side-effect, up to 14 days post-intervention
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will receive an ultrasound-guided bilateral GONB (distal approach) of 5 mLs of injectate of bupivacaine 0.25% (5 mLs) + depomedrol 40 mg in 1 mL (3 mLs to each side).
Time frame: 30 minutes post intervention
The difference in the change in intensity of headache, as measured on an 11-point Numerical Rating Scale (NRS), measured 30 minutes after the intervention, after being positioned in an upright position for 10 minutes, compared to baseline.
Time frame: day 1,3,7,14
The difference in the change in intensity of headache, as measured on an 11-point Numerical Rating Scale (NRS) where 0 means no pain and 10 worst pain imaginable
Time frame: at 30 minutes post-intervention and on the morning of day 1, 3, 7, and 14 post-intervention
The time of onset or worsening of headache when positioned in a sitting position
Time frame: at 30 minutes post-intervention and on the morning of days 1, 3, 7, and 14 post-intervention (in minutes
The duration of tolerance in an upright position (i.e. how long the patient can stay in an upright position until the headache becomes unbearable and urges the patient to lie down))
Time frame: at 30 minutes post-intervention and on days 1, 3, 7, and 14 post-intervention
To assess the impact of SIH-associated symptoms such as tinnitus, tremor, and balance abnormalities
Time frame: at day 14 post-intervention
Emotional functioning as measured by the Generalized Anxiety Disorder-7 items (GAD-7)
Time frame: at day 14 post-intervention
patient impression of change, as measured by the Participant Global Impression of Change (PGIC)
Time frame: daily up to day 14
Analgesic requirement will be measured daily, by intake frequency and dose of analgesics and average daily oral morphine equivalent (OME) in mg
Time frame: daily up to day 14
Time frame: at Day 14 post-intervention
Emotional functioning as measured by the Pain Catastrophizing Scale (PCS)
Time frame: at Day 14 post-intervention
Emotional functioning as measured by the Patient Health Questionnaire for Depression-9-items (PHQ-9)
Contact information is provided by the study sponsor or research team.
University Health Network, Toronto
Other
Role of Greater Occipital Nerve Block in Headache From Spontaneous Intracranial Hypotension: a Prospective Observational Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07582744
Brain Diseases, Central Nervous System Diseases
Durham, North Carolina, United States
View Trial DetailsNCT05922514
Brain Diseases, Central Nervous System Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT07085260
Brain Diseases, Central Nervous System Diseases
Seoul, South Korea
View Trial DetailsNCT07602556
Brain Diseases, Central Nervous System Diseases
View Trial Details